S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

VanEck Vectors Pharmaceutical ETF Stock Forecast, Price & News

-0.70 (-0.94%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
38,837 shs
Average Volume
73,043 shs
Market Capitalization
$329.51 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PPH News and Ratings via Email

Sign-up to receive the latest news and ratings for VanEck Vectors Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer Van Eck
Fund NameVanEck Vectors Pharmaceutical ETF
Tax ClassificationRegulated Investment Company
Inception Date12/20/2011
Fund ManagerHao-Hung Peter Liao, Guo Hua Jason Jin

Fund Focus

Asset ClassEquity
BenchmarkMarket Vectors US Listed Pharmaceutical 25 Index
FocusHealth Care
Development LevelDeveloped Markets

Fund Statistics

Assets Under Management$172.45 million
Average Daily Volume$38.06 thousand

ETF Expenses

Management Fee0.35%
Other Expenses0.05%
Total Expenses0.40%
Fee Waiver-0.05%
Net Expenses0.35%

Administrator, Advisor and Custodian

AdministratorVan Eck Associates Corporation
AdvisorVan Eck Associates Corporation
CustodianThe Bank of New York Mellon Corporation
DistributorVan Eck Securities Corporation
Transfer AgentThe Bank of New York Mellon Corporation
Lead Market MakerIMC Chicago

Geographic Exposure of PPH

Currency Exposure of PPH

Sector Exposure of PPH

Industry Exposure of PPH

VanEck Vectors Pharmaceutical ETF (NASDAQ:PPH) Frequently Asked Questions

How has VanEck Vectors Pharmaceutical ETF's stock price been impacted by Coronavirus (COVID-19)?

VanEck Vectors Pharmaceutical ETF's stock was trading at $56.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PPH shares have increased by 29.6% and is now trading at $73.42.
View which stocks have been most impacted by COVID-19

Are investors shorting VanEck Vectors Pharmaceutical ETF?

VanEck Vectors Pharmaceutical ETF saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 203,900 shares, a drop of 28.1% from the October 31st total of 283,400 shares. Based on an average daily volume of 33,300 shares, the short-interest ratio is presently 6.1 days.
View VanEck Vectors Pharmaceutical ETF's Short Interest

How often does VanEck Vectors Pharmaceutical ETF pay dividends? What is the dividend yield for VanEck Vectors Pharmaceutical ETF?

VanEck Vectors Pharmaceutical ETF declared a quarterly dividend on Thursday, September 30th. Shareholders of record on Monday, October 4th will be given a dividend of $0.345 per share on Thursday, October 7th. This represents a $1.38 annualized dividend and a dividend yield of 1.88%. The ex-dividend date of this dividend is Friday, October 1st. This is a positive change from VanEck Vectors Pharmaceutical ETF's previous quarterly dividend of $0.29.
View VanEck Vectors Pharmaceutical ETF's dividend history

Is VanEck Vectors Pharmaceutical ETF a good dividend stock?

VanEck Vectors Pharmaceutical ETF pays an annual dividend of $1.25 per share and currently has a dividend yield of 1.68%.
View VanEck Vectors Pharmaceutical ETF's dividend history.

What is Bruce Gordon's approval rating as VanEck Vectors Pharmaceutical ETF's CEO?

38 employees have rated VanEck Vectors Pharmaceutical ETF CEO Bruce Gordon on Glassdoor.com. Bruce Gordon has an approval rating of 98% among VanEck Vectors Pharmaceutical ETF's employees. This puts Bruce Gordon in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of VanEck Vectors Pharmaceutical ETF's key competitors?

What other stocks do shareholders of VanEck Vectors Pharmaceutical ETF own?

What is VanEck Vectors Pharmaceutical ETF's stock symbol?

VanEck Vectors Pharmaceutical ETF trades on the NASDAQ under the ticker symbol "PPH."

Who are VanEck Vectors Pharmaceutical ETF's major shareholders?

VanEck Vectors Pharmaceutical ETF's stock is owned by many different institutional and retail investors. Top institutional shareholders include Moors & Cabot Inc. (2.45%), Clough Capital Partners L P (2.07%), Morgan Stanley (1.36%), Orion Portfolio Solutions LLC (1.26%), Commonwealth Equity Services LLC (0.38%) and Royal Bank of Canada (0.34%).

Which major investors are selling VanEck Vectors Pharmaceutical ETF stock?

PPH stock was sold by a variety of institutional investors in the last quarter, including Advisor Group Holdings Inc., Barclays PLC, Orion Portfolio Solutions LLC, All Season Financial Advisors Inc., and Wintrust Investments LLC.

Which major investors are buying VanEck Vectors Pharmaceutical ETF stock?

PPH stock was purchased by a variety of institutional investors in the last quarter, including Moors & Cabot Inc., Clough Capital Partners L P, Belvedere Trading LLC, Vontobel Holding Ltd., Morgan Stanley, Citadel Advisors LLC, UBS Group AG, and Royal Bank of Canada.

How do I buy shares of VanEck Vectors Pharmaceutical ETF?

Shares of PPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VanEck Vectors Pharmaceutical ETF's stock price today?

One share of PPH stock can currently be purchased for approximately $73.42.

How much money does VanEck Vectors Pharmaceutical ETF make?

VanEck Vectors Pharmaceutical ETF has a market capitalization of $329.51 million.

How many employees does VanEck Vectors Pharmaceutical ETF have?

VanEck Vectors Pharmaceutical ETF employs 147,000 workers across the globe.

How can I contact VanEck Vectors Pharmaceutical ETF?

The company can be reached via phone at 14089961010.

This page was last updated on 11/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.